Earnings ·
ALX Oncology Holdings Inc. reported financial results for the second quarter ended June 30, 2026, on August 6, 2026
ALXOAlx Oncology Holdings Inc
ALX Oncology Holdings Inc. reported financial results for the second quarter ended June 30, 2026, on August 6, 2026. The company posted a GAAP net loss of $18.0 million, or $0.13 per share, compared to a $25.9 million loss in the prior year period. Cash, cash equivalents, and investments totaled $153.4 million as of June 30, 2026. The company strengthened its balance sheet by refinancing existing debt with HSBC Ventures USA Inc., securing up to an additional $20 million draw through June 2028 under a new facility totaling up to $50 million. Leadership appointments included Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel. Clinical updates indicated enrollment remains on track for the Phase 2 ASPEN-09-Breast trial evaluating evorpacept, with topline data expected in mid-2027, while initial safety data for ALX2004 is anticipated in the second half of 2026. ALX Oncology Holdings Inc. operates as a clinical-stage biotechnology company advancing novel cancer therapies.